Eli Lilly stock gets a USD 870 million Gate deal expansion

Published on 10/06/2026 at 14:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eli Lilly stock follows a USD 870 million collaboration expansion announced on October 5, 2026. Q2 revenue rose 47.7 percent to USD 22.97 billion.

Schwarzweiß-Reportagefoto von Mitarbeitern an einer Tablettenproduktionslinie — Dokumentarische Schwarzweiß-Aufnahme repräsentiert Eli Lilly and Company, ISIN US5324571083, in pharmazeutischer Produktionsstätte weltweit, Illustration mit AI erstellt.

Eli Lilly and Company stock (ISIN US5324571083) closed at USD 1,143.12 on October 5, 2026, up USD 0.27 or 0.02 percent on the NYSE. The company expanded its Gate Bioscience drug-discovery collaboration in a deal potentially worth more than USD 870 million, according to Reuters on October 5, 2026.

Gate deal broadens Lilly pipeline

The expanded agreement adds one drug target and gives Lilly the option to add a second, while Gate receives upfront funding, research support and potential milestone payments. Yahoo Finance reported that Lilly will hold exclusive worldwide rights and manage later-stage development, manufacturing and commercialization.

The value is contingent on development and commercial milestones rather than an immediate payment of USD 870 million. That makes the agreement strategically relevant, but its financial impact depends on whether the molecular-gate programs produce viable medicines.

Q2 revenue sets the operating benchmark

Lilly reported USD 22.97 billion in Q2 2026 revenue, up 47.7 percent from the prior year and ahead of the USD 20.69 billion consensus, according to Yahoo Finance. Management also raised full-year 2026 revenue guidance to USD 85 billion to USD 87 billion, keeping growth expectations closely tied to Mounjaro and Zepbound demand.

The next operating checkpoint is Lilly's Q3 2026 earnings call on October 29, 2026, listed on the company's investor-relations page at Eli Lilly. The timing gives investors a defined test for whether the second-quarter growth rate is continuing into the second half.

Analyst target stays above the stock

MarketBeat reports a Moderate Buy consensus from 30 analysts, with 25 Buy ratings, a USD 1,311.96 average target, a USD 900.00 low and a USD 1,600.00 high. The average target lies 14.8 percent above the October 5 closing price.

JPMorgan raised its target from USD 1,400 to USD 1,500 on September 28, 2026, while maintaining an Overweight rating, according to MarketBeat. The target move contrasts with the stock's limited 0.02 percent gain in the latest completed session.

Stock remains below its yearly high

Eli Lilly stock closed at USD 1,143.12 on the NYSE on October 5, 2026, with a 52-week range of USD 783.85 to USD 1,292.65. The closing price was USD 149.53 below the yearly high, while market capitalization stood at USD 1.0 trillion.